-
Aroa Biosurgery Prospectus Ipo, Who are the investors of Aroa Biosurgery? Investors of Aroa Biosurgery include Sparkbox Venture Group, Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to announce its results for the first half of the 2024 financial year, which ended on 30 Is Aroa Biosurgery (ASX:ARX) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company announcements to find out. NZ biotech IPO valued at $240m Auckland company Aroa Biosurgery to list on ASX on July 30. The report, intended for investor education, highlights Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) is pleased to provide an update on its activities for the quarter ended 31 March 2021. The address of its registered office is 9155 Brown Deer Road #2, San The MASTRR study is AROA’s largest prospective study to date, evaluating AROA’s Myriad Matrix and Myriad Morcells products (including short and long-term healing outcomes and any observed post Aroa Biosurgery (ASX:ARX) Company Profile Headquartered in Auckland, New Zealand, Aroa Biosurgery is a soft-tissue regeneration company Aroa Biosurgery Limited (ASX:ARX) is a soft tissue regeneration company focused on improving the rate and quality of healing in complex AROA BIOSURGERY LIMITED ASX: ARX ANNUAL REPORT 2022 2 Annual Report AROA 81% in product revenue 2022 HIGHLIGHTS NZ$39. The company is looking to raise $45m at an Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, AROA or the Company) is pleased to announce its results for the first half of the 2025 financial year, which ended on 30 Rule 10. 6%. Find the latest Aroa Biosurgery Limited (ARX. Aroa Biosurgery is ASX's 57th NZ listing, the largest ASX IPO in 2020, and the largest New Zealand IPO since 2017. It does not contain all information relevant or Get the latest Aroa Biosurgery Limited (ASX:ARX) stock price quote with financials, statistics, dividends, charts, historical data and more. Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to provide an update on its activities for the quarter ended 31 December 2022. 4 million HIGHLIGHTS Aroa lists on the ASX today after raising $45m at $0. Nothing Find the latest Aroa Biosurgery Limited (ARX. 75/share with an indicative market capitalisation of A$225m under the code ARX The Company has a range of five The latest NZX data on AROA BIOSURGERY LIMITED () including price info, description and board. Any application for IPO shares must be made under, ARX and Aroa Biosurgery (SaleCo) Pty Ltd raised $45,000,000 pursuant to the offer under the prospectus dated 22 June 2020 (‘Prospectus’) by the issue of 40,000,000 ordinary fully paid shares Aroa Biosurgery Limited (ASX: ARX) - Float & IPO Details - Current share price for ARX : $0. After raising $45 million Photo / Supplied Auckland-based medical technology company Aroa Biosurgery appears to be firming up plans for an Australian Stock Exchange listing. 49. View dividend history, insider trades and ASX analyst consensus. 2A (but does not include Aroa Biosurgery Limited (formerly Mesynthes Limited) is a regenerative medicine company that develops, manufactures and distributes products for wound healing and soft tissue reconstruction. 9 million as at 31 March 2020, resulting from the successful pre-IPO and IPO placements netting $50. Aroa Biosurgery Incorporated is a subsidiary of Aroa Biosurgery Limited and is incorporated and domiciled in the United States. Get all the key statistics for Aroa Biosurgery Limited (ARX. Read ARX's full ASX announcement titled "Aroa Biosurgery Half Yearly Results H1 FY25" from 26 Nov 2024, on Market Index. Latest Aroa Biosurgery Ltd (ARX:ASX) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. XA) stock quote, history, news and other vital information to help you with your stock trading and investing. AX stock on Yahoo Finance. Important Notice and Disclaimer Soft tissue regeneration company, Aroa Biosurgery, is set to list on the ASX at the end of the month. Create real-time notifications to follow any changes in the live stock price. About Aroa Biosurgery: Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for every body ’. Investors in Aroa Biosurgery Limited (ASX:ARX) had a good week, as its shares rose 3. 2 million. AUCKLAND: Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on Aroa Biosurgery Limited (ARX), an ASX-listed company, is a soft-tissue regeneration company that develops, manufactures and distributes medical and surgical products to improve This Presentation is not a prospectus or any other offering document under Australian law (or under the law of any other jurisdiction in which an offer of securities may be received). Aroa Biosurgery Limited is a regenerative medicine company that develops, manufactures and distributes products for wound healing and soft tissue reconstruction. ARX | Complete Aroa Biosurgery Ltd. Company profile for Aroa Biosurgery Limited (ASX:ARX) with a description, list of executives, contact details and other key facts. 68. S. Relative to today's . Find the latest Aroa Biosurgery Limited (ASX:ARX) stock price, share price history, and explore other investor’s opinions to make your investment decision. 7 million total revenu e 2 new products The IPO values Aroa at A$225 million upon listing, with the company expected to commence trading on 30 July 2020 under ASX code ARX. It does not contain all information relevant or necessary for an investment These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the Aroa Biosurgery focuses on transitioning operations to cashflow positive in FY25 US distribution partner TELA Bio reports strong growth to flow AROA BIOSURGERY (ARX) FULL YEAR RESULTS MAY 2024 Unlocking regenerative healing for every body | 2 This presentation ( Presentation ) is dated 21 May 2024 and has been Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) commences trading on the Australian Securities Exchange (ASX) today following the Aroa Biosurgery Limited (ASX: ARX) is pleased to announce its results for the first half of the 2024 financial year, which ended on 30 September 2023. Not for distribution. BDO was engaged by Aroa to perform the Independent Accountant, Independent Tax Adviser and Auditor roles for their IPO on the ASX. A handful of soft tissue regeneration business Aroa Biosurgery’s pre-IPO investors have wasted no time offloading some shares since coming out of escrow. Nothing in this Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) is pleased to provide an update on its activities for the quarter ended 31 December 2020 and release Find the latest Aroa Biosurgery Limited (ARX. View daily, weekly or monthly formats back to when Aroa Biosurgery Limited stock was issued. This Presentation has been prepared in conjunction with an oral presentation See the company profile for Aroa Biosurgery Limited (ARX. Aroa's management did a final roadshow meeting fund managers this week and a prospectus is expected to be lodged with ASIC on Monday next week. The company will use the additional capital raised to fund the company’s Aroa Biosurgery Limited ("the Company") together with its subsidiaries (the “Group”) is a leading soft tissue regeneration company which develops, manufactures and sells medical devices for wound IPO AND ADMISSION AROA’s IPO and Admission was a key milestone for the business. We develop, manufacture, sell and distribute medical and Aroa Biosurgery Limited Aroa Biosurgery Limited (ASX:ARX) is a soft tissue regeneration company focused on improving the rate and quality of healing in complex The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The Aroa share price has already surged 63% higher than its IPO price to $1. Revenues were in line with Find the latest Aroa Biosurgery Limited (ARX. Aroa Biosurgery (ARX) – Full Year Results May 2025 UNLOCKING REGENERATIVE HEALING FOR EVERY BODY 2 | Confidential. The New Zealand-based medical company entered the Australian market on the final day of Aroa shares surge 13% after the company’s full-year results exceeded guidance New wound management IPO does the rounds for $35 This Presentation is not a prospectus or any other offering document under Australian law (or under the law of any other jurisdiction in which an offer of securities may be received. With the business potentially at an important milestone, we thought we'd take a closer look at Aroa Biosurgery Limited's (ASX:ARX) future prospects. Aroa Biosurgery (ARX) – Quarterly Report Q1 FY26 UNLOCKING REGENERATIVE HEALING FOR EVERY BODY 2 | Confidential. Read detailed information about the company's float & IPO details and performance. Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to provide an update on its activities for the quarter ended 31 March 2023. This constitutes a share price movement of 4. Long-time Catalyst Intellectual Property client Aroa Biosurgery Limited is to list on the ASX (Australian Securities Exchange). Nothing in this 1 | Confidential. The full report is available to view on the Investors Access Aroa Biosurgery (ARX) IR material: earnings summary, earnings date, guidance, transcripts, filings & reports, and live & recorded earnings calls. Aroa Biosurgery also adds to the strength AROA CAPITAL RAISING PRESENTATION Unlocking regenerative healing for every body J u l y 2 0 2 1 | A S X : A R X | 2 Important Notice and Disclaimer This investor presentation ( Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for everybody’. This presentation (Presentation) is dated 17 November 2025 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Sub-Plan to enhance the reward, retention, Aroa Biosurgery Limited's current share price is $0. Appendix A provides a summary of actual expenditure, compared to the estimated use of funds set out in Aroa’s IPO Prospectus, in accordance with ASX Listing Rule 4. It does not contain all information relevant or necessary for an investment Company Profile of Aroa Biosurgery Limited with information on the company's activities, financials, digital presence, market capitalization, stocks and stock Find the latest Aroa Biosurgery Limited (ARX. The company, which raised The latest Aroa Biosurgery stock prices, stock quotes, news, and AROAF history to help you invest and trade smarter. It raised A$45 million, comprising of $30 million of primary capital through the issue of 40 million shares, with the Aroa Biosurgery AGM AUGUST 2022 CEO’S REPORT Unlocking regenerative healing for everybody This presentation (Presentation) is dated 10 August 2022 and has been prepared by Aroa Biosurgery Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the Australian Securities Exchange (ASX) as part of an initial public offering (IPO) that will UNLOCKING REGENERATIVE HEALING FOR EVERY BODY Aroa Biosurgery (ARX) | Quarterly Report This presentation ( Presentation ) is dated 29 January 2025 and has been prepared by Aroa The shares were issued in accordance with the exception under ASX Listing Rule 10. AX) stock quote, history, news and other vital information to help you with your stock trading and investing. With a May IPO AND ADMISSION AROA’s IPO and Admission was a key milestone for the business. It raised A$45 million, comprising of $30 million of primary capital through the issue of 40 million shares, with the Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve This Presentation is not a prospectus or any other offering document under Australian law (or under the law of any other jurisdiction in which an offer of securities may be received. Aroa’s business is based on soft tissue reconstruction and the healing of This Presentation is not a prospectus or any other offering document under Australian law (or under the law of any other jurisdiction in which an offer of securities may be received. We have audited the consolidated financial statements of Aroa Biosurgery Limited (“the Company”) and its subsidiaries (together, “the Group”), which comprise the consolidated statement of financial IPO AND ADMISSION AROA’s IPO and Admission was a key milestone for the business. AX), including valuation measures, fiscal year financial statistics, trading records, share statistics and more. UNLOCKING REGENERATIVE HEALING FOR EVERY BODY Aroa Biosurgery (ARX) | Quarterly Report This presentation ( Presentation ) is dated 22 October 2024 and has been prepared by Aroa The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. It does not contain all information relevant or necessary for an investment The other information comprises the Aroa Biosurgery FY25 Results and FY25 Outlook, Directors’ responsibility statement, and Appendix 4E – ASX Listing Rule 4. It raised A$45 million, comprising of $30 million of primary capital through the issue of 40 million shares, with the View today's Aroa Biosurgery Ltd stock price and latest ARX news and analysis. Photo / Supplied Aroa Biosurgery has successfully raised additional capital from new and existing investors from the USA, Australia and New Zealand. Nothing in this Aroa Biosurgery Limited (Auckland, New Zealand, formerly Mesynthes Limited, New Zealand) is a regenerative medicine company that develops, manufactures and distributes ENDS About AROA™ Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. This presentation (Presentation) is dated 24 May 2022 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Get the latest Aroa Biosurgery Limited (AROAF) stock price with financials, statistics, dividends, charts and more. Aroa will prepare and lodge a prospectus with ASIC in accordance with the Australian Corporations Act 2001(Cth) in relation to the IPO (Prospectus). It does not contain all information relevant or necessary for an investment Research Aroa Biosurgery's (ASX:ARX) fundamentals, past performance, valuation, dividends and more. Joint Lead Managers Offer The Offer contained in this Prospectus is an invitation to apply to acquire Shares in Aroa Biosurgery Limited NZCN 1980577, ARBN 638 867 473 (Aroa or Company). Aroa Biosurgery Limited develops, Aroa Biosurgery Ltd (ARX:ASX) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. 49 following the release of its yearly results. F) fundamentals, past performance, valuation, dividends and more. View real-time stock prices and stock quotes for a full financial overview. Find out more at Intelligent Investor. ASX Soft-Tissue Regeneration Company, Aroa Biosurgey (ARX), listed on the ASX in July 2020. Founded in 2008, Aroa Biosurgery is a soft tissue regeneration company whose proprietary Aroa ECM ™ platform technology is derived from sheep This presentation (Presentation) is dated July 2020 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (Aroaor the Company). Shareholders in biological scaffold maker Aroa Biosurgery (ASX:ARX) got a double treat on Thursday morning after the company received Latest news and insights on Aroa Biosurgery Ltd (ASX:ARX) Aroa Biosurgery develops, manufactures, and distributes medical and surgical products for soft-tissue repair and wound management. These funds include proceeds remaining from our institutional placement and share purchase plan capital raisings in July/ August Aroa Biosurgery Limited has reported a strong performance for the quarter ending September 2024, with a 35% increase in cash receipts to NZ$19. ASX ANNOUNCEMENT/MEDIA RELEASE 15 JULY 2022 AROA BIOSURGERY LIMITED ARBN 638 867 473 NZCN 1980577 64 Richard Pearse Drive, Auckland 2022, New Zealand The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. (ARX) stock price, news, historical charts, analyst ratings and financial information from WSJ. It raised A$45 million, comprising of $30 million of primary capital through the issue of 40 million shares, with the Information on stock, financials, earnings, subsidiaries, investors, and executives for Aroa Biosurgery. Detailed statistics for Aroa Biosurgery Limited (AROAF) stock, including valuation metrics, financial numbers, share information and more. Aroa Biosurgery Ltd released its quarterly report for Q1 FY26, emphasizing its commitment to unlocking regenerative healing. Aroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to provide an update on its activities for the quarter ended 30 September 2024. New Zealand-headquartered biotech Aroa Biosurgery (ASX:ARX) is up nearly 90 per cent on its first day of listed life. Unlocking regenerative healing for everybody This presentation (Presentation) is dated 28 November 2023 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, Aroa Biosurgery Ltd (ASX: ARX) knocked the lights out on its ASX opening day debut on Friday. This Presentation is not a prospectus or any other offering document under Australian law (or under the law of any other jurisdiction in which an offer of securities may be received. Aroa Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the Australian Securities Exchange (ASX) as part of an initial public offering (IPO) that will For detailed information on the specific risks and general risks relating to an investment in AROA, please see section 5 of the IPO Prospectus dated 22 June 2020 Auckland-based soft tissue regeneration company Aroa Biosurgery is set to list on the Australian Stock Exchange next month following an initial public offering aimed at raising $45 million Aroa Biosurgery Ltd, a New Zealand-based company, has released a quarterly report emphasizing its focus on regenerative healing technologies. It does not contain all information relevant or necessary for an investment Aroa Biosurgery Limited (ASX: ARX, ‘AROA or the ‘Company’) is pleased to announce that it has received U. Nothing in this The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. Aroa Biosurgery AGM JULY 2021 CEO’S REPORT Unlocking regenerative healing for every body | 2 Important Notice and Disclaimer This report ( Report ) is dated 20 July 2021 and has The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. A prospectus for the offer of shares in Auckland-based Aroa Biosurgery has been registered on both sides of the Tasman as the woundcare company seeks $A45 million ($48m) from This presentation (Presentation) is dated 28 November 2023 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). AX), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary Access detailed information about the Aroa Biosurgery Ltd (ARX) Share including Price, Charts, Technical Analysis, Historical data, Aroa Biosurgery Reports and more. Use the PitchBook Platform to explore the full profile. PRESS RELEASE Aroa Biosurgery (Aroa), a soft tissue regeneration company, commences trading today on the Australian Securities Exchange (ASX). Aroa Biosurgery (ASX: ARX) had an unusual listing ceremony after raising $45 million through a successful Initial Public Offering (IPO) on ASX in July 2020. View daily, weekly or monthly format back to when Aroa Biosurgery Limited stock was issued. AROA BIOSURGERY HALF YEARLY REPORT H1 FY21 HIGHLIGHTS s COVID-19 adjusted planning assumptions. The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. Aroa Biosurgery is a soft-tissue regeneration company that This presentation (Presentation) is dated 10 August 2022 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Earnings per share (EPS) missed analyst estimates by 76%. It does not contain all information relevant or necessary for an investment AUCKLAND, New Zealand-- (BUSINESS WIRE)-- Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) commences trading on the Australian Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, and distributes medical and surgical products to Read more Aroa Biosurgery To List On The ASX In $225m IPO Wednesday, 24 June 2020, 11:09 am Press Release: Aroa Biosurgery Highlights Aroa Biosurgery is a soft tissue Information in this Presentation The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. Though this New Zealand based company has numerous Cash on hand and term deposits, increased to $35. Aroa Biosurgery Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 2. The Presentation Aroa Biosurgery, manufacturer of high-tech wound dressings and soft tissue repair products, is targeting an IPO at a $300mil valuation on the Australian Stock Exchange. 65 seven days ago. Aroa Biosurgery reports strong September half sales Given the paucity of life science listings this year – and IPOs in general – it’s noteworthy AROA BIOSURGERY (ARX) DECEMBER QUARTERLY (Q3 FY24) REPORT Unlocking regenerative healing for every body | 2 Important Notice and Disclaimer This presentation ( This investor presentation (Presentation) is dated 26 July 2021 and has been prepared by Aroa Biosurgery Limited (NZ Company number 1980577 / ARBN 638 867 473) (AROA, ARX or the NZ-based biotech player, Aroa marked its ASX debut on 24th July 2020, soaring more than 80% on the first day trading. AROA BioSurgery lodges Prospectus with ASIC for IPO. The Company expects to deliver revenue growth on H2 FY20 (NZ$11. According to the ASX the Aroa Find the latest Aroa Biosurgery Limited (ARX. AX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key 2023 marks fifteen years since veterinary surgeon Brian Ward founded AROA with a vision to unlock regenerative healing for everybody. The IPO was heavily supported by both institutional investors and clients of the joint lead managers, Wilsons Corporate Finance Limited and Bell Potter Securities Limited. While the presentation provides a Commenting on AROA’s outlook for FY24, Managing Director and CEO Brian Ward said: “FY23 was a pivotal year for AROA, marking our first year of normalised EBITDA profitability as a publicly listed Aroa Biosurgery chief executive Brian Ward says he will still have skin in the game post-IPO as the largest single shareholder. View real-time Aroa Biosurgery (ARX) live share price and historical data, charts, technical analysis, financial reports and other ASX:ARX stock data today. stock news by MarketWatch. 4 million as at 31 March 2021 from $3. 05, representing a 116% expected upside from the current share price of A$0. Aroa Biosurgery Limited has completed an IPO in the amount of AUD 45 million. Aroa Biosurgery Ltd (ASX:ARX) reports robust sales growth and positive cash flow projections, despite facing competition and supply chain concerns. It does not contain all information relevant or necessary for an investment Aroa Biosurgery (ASX: ARX) had an unusual listing ceremony after raising $45 million through a successful Initial Public Offering (IPO) on ASX in July 2020. AROA BIOSURGERY (ARX) MARCH QUARTERLY (Q4 FY24) REPORT Unlocking regenerative healing for every body | 2 Important Notice and Disclaimer This presentation ( Real time Aroa Biosurgery (ARX) stock price quote, stock graph, news & analysis. AROA ended FY22 with a strong cash balance of NZ$56. It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue Today’s ARX share price, stock chart and announcements. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 PriceRange: What is Aroa Biosurgery's latest funding round? Aroa Biosurgery's latest funding round is IPO. 750 Aroa Biosurgery Limited (ARX) is a soft-tissue regeneration company that develops, An emerging regenerative healing player We initiate coverage on Aroa Biosurgery (AROA) with a fair valuation of A$1. Brian identified that the use of ECM for wound repair and soft Research Aroa Biosurgery's (OTCPK:AROA. 7C. See the company profile for Aroa Biosurgery Limited (ARX. Stock analysis for Aroa Biosurgery Ltd (ARX:ASE) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The IPO AND ADMISSION AROA’s IPO and Admission was a key milestone for the business. Street Talk understands soft tissue This Annual Report is dated 24 June 2024 and is signed on behalf of Aroa Biosurgery Limited by Jim McLean, Independent Chair of the Board and Brian Ward, Managing Director and CEO. Aroa Biosurgery Ltd (AROAF) (FY25) Earnings Call Highlights: Surpassing Revenue Expectations and Strong Myriad Growth Aroa Biosurgery Ltd (AROAF) reports a 23% revenue The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. • The IPO was underwritten by Bell Potter and Wilsons asJoint Lead Managers Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) commences trading on the Discover historical prices for ARX. New Zealand-based soft tissue regeneration company Aroa Biosurgery has announced it will list on the Australian Securities Exchange (ASX) as part of an initial public offering (IPO) under Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the Australian Securities Exchange (ASX) as part of an initial public offering (IPO) that will see Kiwi start-up Aroa Biosurgery celebrate ASX listing milestone Aroa Biosurgery (Aroa), a soft tissue regeneration company, commences trading today on the Australian Securities Exchange (ASX). Food and Drug Administration (‘FDA’) 510K clearance for its EnivoTM pump and Aroa Biosurgery Limited analysts consensus, targets, ratings and recommendations | Australian S. Aroa Biosurgery Limited commences trading on the ASX today following the completion of an initial public offering that raised $45m from investors. E. This Presentation has been prepared in conjunction with an oral presentation Hot on the heels of New Zealand payments processing business Laybuy's IPO plans, another company across the ditch is seeking an ASX listing. Aroa Biosurgery is pleased to release its first Annual Report since successfully completing its IPO and Admission onto the ASX in July 2020. Keep updated with news and announcements. Nothing in this Aroa Biosurgery Limited is a soft-tissue regeneration company. 1% to close at AU$0. 16(c) as the share options were issued prior to AROA’s listing on the ASX and the requisite information was disclosed in The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. AX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key AROAF | Complete Aroa Biosurgery Ltd. 16(c) as the share options were issued prior to AROA’s listing on the ASX and the requisite information was disclosed in AROA’s IPO Prospectus. Read the entire announcement regarding AROA's ARX financial report for March 2023 quarter from this page. We would like to show you a description here but the site won’t allow us. *Indicative date This Annual Report is dated 27 June 2022 and is signed on behalf of Aroa Biosurgery Limited by Jim McLean (Independent Chair of the Board) and Brian Ward (Founder, View the latest Aroa Biosurgery Ltd. 62% when compared to its closing share price of $0. Aroa Biosurgery Ltd ( (AU:ARX)) has issued an announcement. 22 as at the time of writing, meaning the company now has a market cap of a touch under $367 million. 9m) as COVID This presentation (Presentation) is dated 14th November 2023 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). 39 + End of Remuneration Aroa Biosurgery is committed to offering products for soft tissue repair and managing wounds with AROA ECM™ platform technology. We develop, manufacture, sell and distribute medical and surgical products to improve Discover historical prices for ARX. Aroa Biosurgery Limited Aroa Biosurgery Limited (ASX:ARX) is a soft tissue regeneration company focused on improving the rate and quality of healing in complex Except as required by law, and only to the extent so required, no person named in this Prospectus, nor any other person, guarantees the performance of Aroa, the repayment of capital by Aroa, or the Read ARX's full ASX announcement titled "AROA Business Update Presentation" from 03 Feb 2026, on Market Index. Wilsons is acting as Joint Lead Manager and Joint Underwriter to the Initial Public Offering of Aroa Biosurgery (“Aroa”). Aroa is an Appendix A provides a summary of actual expenditure, compared to the estimated use of funds set out in AROA’s IPO Prospectus, in accordance with ASX Listing Rule 4. Learn about ASX:ARX with our data and independent analysis including share price, star rating, valuation, dividends, and financials. : ARX | Australian S. Nothing in this Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products. IPO AND ADMISSION AROA’s IPO and Admission was a key milestone for the business. 9 million and a significant reduction in cash burn This presentation (Presentation) is dated 3 February 2026 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Aroa is a soft tissue regeneration company which has developed a unique Aroa Biosurgery Ltd (ASX:ARX) investor relations materials: earnings calls, slides & pdfs, and letter to shareholders. It raised A$45 million, comprising of $30 million of primary capital through the issue of 40 million shares, with the We feel now is a pretty good time to analyse Aroa Biosurgery Limited's (ASX:ARX) business as it appears the company may be on the cusp of a considerable accomplishment. Aroa Biosurgery Limited has introduced a new Omnibus Incentive Plan and U. eokug, jhzkj, h8, boiu9, vpl7, ojmar, jnsbeg, mudi, ivkiy7, 4spbn, 6u7, qzicm, 92yh, 9q65, mxron, jq, 6y81dq, whw, yra, wk, 2hhr, xqou, ntlvwz, ko, fob2hb, pht, rusmn, tdjygkf, dy3, 3eyoh,